Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice

Journal of Pathology

Volumn 188, Issue 3, 1999, Pages 322-328

  McDonnell, Timothy J ^a   Montes De Oca Luna, Roberto ^b   Cho, Song ^a   Amelse, Lisa L ^a   Chavez Reyes, Arturo ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

Lymphomas; mdm2; Mouse models; p53; Sarcomas; Transgenic mice; Tumour suppressor genes

Indexed keywords

ALLELE; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; GENE DELETION; GENE DOSAGE; GENE LOSS; HETEROZYGOSITY; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; FEMALE; GENES, P53; LOSS OF HETEROZYGOSITY; LYMPHOMA; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA, EXPERIMENTAL; TERATOCARCINOMA; TERATOMA; TESTICULAR NEOPLASMS;

EID: 0344654959     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F     Document Type: Article

References (32)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
2. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
3. Greenblatt MS, Bennett WP, Holstein M, Haris CC. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
4. Hainaut P, Soussi T, Shomer B, et al. Database of p53 gene somatic mutations in human tumours and cell lines: updated compilation and future prospects. Nucleic Acids Res 1997; 25: 151-157.
5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83.
6. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healy JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993; 53:16-18.
7. Momand J, Zambetti GP. Mdm-2: 'Big brother' of p53. J Cell Biochem 1997; 64: 343-352.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
9. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-4114.
10. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860.
11. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997; 11: 1974-1986.
12. Freedman DA, Epstein CB, Roth JC, Levine AJ. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997; 3: 248-259.
13. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to the p53 tumour suppressor transactivation domain. Science 1996; 274: 948-953.
14. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
15. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
16. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
17. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
18. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994; 54: 794-799.
19. Lundgren K, Montes de Oca Luna R, McNeill YB, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997; 11: 714-725.
20. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.
21. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB, Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-694.
22. Marechal V, Elenbaas B, Piette J, Nicolas JC, Levine AJ. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol 1994; 14: 7414-7420.
23. Benbaas B, Dobbelstein M, Roth J, Shenk T, Levine AJ. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol Med 1996; 2:439-451.
24. Jacks T, Remington L, Williams BO, et al. Tumour spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
25. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
26. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998; 17: 2513-2525.
27. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 1993; 13: 301-306.
28. Weinberg RA. E2F and cell proliferation: a world turned upside down. Cell 1996; 85: 457-459.
29. Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. Tumour induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 537-548.
30. Field SJ, Tsai F-Y, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-561.
31. Jones SN, Sands AT, Hancock AR, et al. The tumourigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A 1996; 93: 14 106-14 111.
32. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumours from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667.